TalalHilalMD

Hematology • Phoenix, AZ

Hematologic Oncology

Assistant Professor of Medicine

Join to view full profile

Dr. Hilal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hilal's full profile

Already have an account?

Office
5777 E. Mayo Boulevard
Phoenix, AZ 85050

Summary

The Changing Standards for FDA Oncology Approvals: Talal Hilal, MD

The FDA approval process is in place to ensure that drugs are safe and effective before they are made available to the public. But do the clinical trials that l

Substandard control arms question some new cancer drugs' utility - STAT

The rapid pace of new cancer drugs approved by the FDA, 16 in 2018 alone, is - on the surface - good news for people with cancer.

Education & Training

Mayo Clinic College of Medicine and Science (Phoenix)Fellowship, Hematology and Medical Oncology, 2016 - 2019
University of Kentucky College of MedicineResidency, Internal Medicine, 2013 - 2016
Royal College of Surgeons in Ireland - Medical University of BahrainClass of 2012

Certifications & Licensure

AZ State Medical License 2016 - 2026
MS State Medical License 2019 - 2023
OR State Medical License 2018 - 2018
KY State Medical License 2014 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Hematology
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology

Publications & Presentations

PubMed

2 citations
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, Chenyu Lin, Simone E Dekker
Journal of Clinical Oncology. 2025-02-10
Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era.
Paul J Hampel, Kari G Rabe, Yucai Wang, Steven R Hwang, Saad S Kenderian
Leukemia. 2025-02-01
Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism.
Amber B Koehler, Kari G Rabe, Daniel J Crusan, Timothy G Call, Sara J Achenbach
Journal of Thrombosis and Haemostasis. 2025-01-01

Authored Content

Practices in Haematology Contributing to Unnecessary ToxicityApril 2020
The Step 1 Score Reporting Change – A Step in the Right Direction for IMGs?February 2020
A Millennial Doctor’s Experience with Industrial MedicineMay 2019

Press Mentions

Promising Developments in Chronic Lymphocytic Leukemia TreatmentAugust 20th, 2024
Understanding Follicular LymphomaApril 28th, 2024
Control Arm Quality in Randomized Oncology Trials Leading to FDA ApprovalMay 17th, 2019
Join now to see all